Evidence map›Paper›PMID 42262528›Full record

ReviewDiabetologia2026

Unravelling the developmental origins of cystic fibrosis-related diabetes.

Alex Cho, Maria Cristina Nostro

Abstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alex ChoMcEwen Stem Cell Institute, University Health Network, Toronto, ON, Canada.
Maria Cristina NostroMcEwen Stem Cell Institute, University Health Network, Toronto, ON, Canada. Cristina.Nostro@uhn.ca.

Funding

Cystic Fibrosis Foundation NOSTRO23I0
6 · The paper itself

Abstract

Cystic fibrosis (CF)-related diabetes (CFRD) is a growing and evolving concern for people living with cystic fibrosis. As its own unique clinical entity, there is an urgent need to better understand this complex health challenge to improve the quality of life for people with CF. Unfortunately, many aspects of CFRD pathophysiology and pathogenesis remain unclear, resulting in a disparity in the standard of care provided. An emerging body of evidence supports that CFRD may have developmental origins, as people with CF present with pancreatic pathology and glucose abnormalities as early as in utero. This therefore suggests that the CF transmembrane conductance regulator (CFTR) gene mutations that cause CF may impair pancreatic organogenesis, thus leading to CFRD. This review consequently aims to summarise the existing evidence that may support a fundamentally vital role of CFTR in the development of the pancreas. From aspects of the endocrine and exocrine pancreas to scrutinising the broader islet microenvironment, the many constituents at play in pancreatic organogenesis are highlighted. Unravelling the deeper complexities of CFRD pathogenesis will not only clarify existing knowledge gaps but may transform the way future care is provided.

Indexed as

Cystic FibrosisDiabetes MellitusAnimalsCystic Fibrosis Transmembrane Conductance RegulatorHumansMutationPancreasCystic Fibrosis Transmembrane Conductance RegulatorCystic fibrosisCystic fibrosis-related diabetesCystic fibrosis transmembrane conductance regulatorDevelopmentMicroenvironmentOrganogenesisPancreasReview

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.